Optimi Health Corporation (OPTH)

Optimi Health Completes Commercial Psilocybin Production to Address Treatment-Resistant Depression in AustraliaJune 2, 2026 12:36 PM
PR Newswire (Canada) Optimi's 5mg psilocybin capsules are prescribed commercially for treatment-resistant depression in Australia, with additional product from the run earmarked for planned clinical trials in the United States and EuropeVANCOUVER, BC, June 2, 2026 /CNW/ - via IBN – Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "Company" or "Optimi"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the completion of a GMP production run of its 5mg psilocybin finished drug product. The finished psilocybin capsules use the same formulation already prescribed to patients in Australia for treatment-resistant depression ("TRD"). The Company has also updated the product's bottling configuration to improve ease of use for prescribers and patients in the Australian market.Additional product from the same production run is earmarked to support upcoming clinical research in the United States and clinical trials in Europe across various indications.All stages of manufacturing were completed in-house and on-site at Optimi's facility under its Health Canada Drug Establishment Licence ("DEL"): biomass cultivation, extraction of the active pharmaceutical ingredient ("API") using Optimi's proprietary methods, encapsulation of the 5mg finished drug product, and packaging. The DEL authorizes Optimi to manufacture, package, label, test, store, and distribute controlled drug products, positioning the Company as a vertically integrated GMP supply layer for regulated psychedelic medicine.The pharmaceutical grade facility is built to institutional security standards, including a Health Canada compliant Level 8 vault with the capacity to securely store controlled substances valued at up to C$100 million. Optimi is authorized by Health Canada to hold up to 20 kilograms of psilocybin and approximately 2,000 kilograms of biomass on site, giving the Company commercial-scale supply capacity."Optimi is one of the only companies to take naturally derived psilocybin from biomass to a finished drug product, entirely under one roof and on our own licence," said Dane Stevens, CEO and Co-Founder of Optimi. "What sets Optimi apart is that we serve both sides of this market simultaneously. The same  5mg psilocybin medicine prescribed in-clinic for treatment-resistant depression today, within a fully regulated framework, is the drug also being studied in clinical trials across a range of indications. We are proud to supply patients today and the researchers shaping what comes next."Optimi supplies finished psilocybin and MDMA drug products to regulated markets internationally, in support of both patient access and clinical research. Building on its established export capability under the DEL, the Company is positioned to serve approved programs across multiple jurisdictions. Inquiries regarding product for special access programs and clinical trial supply may be directed to sales@optimihealth.ca.About Optimi Health Corp.Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) is a commercial-stage pharmaceutical company focused on manufacturing and distributing GMP-grade psychedelic drug products for mental health therapies. As a Health Canada-licensed pharmaceutical manufacturer, Optimi produces validated MDMA and botanical psilocybin drug products at its GMP-compliant facilities in British Columbia, Canada.Optimi supplies both active pharmaceutical ingredients and finished dosage forms to regulated clinical and therapeutic programs internationally, with products currently prescribed to patients in Australia under the country's Authorized Prescriber Scheme and accessible in Canada through the Special Access Program.For more information, please visit www.optimihealth.ca or optimi.net.Forward-Looking StatementsThis press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws, including statements regarding the Company's ability to supply commercial psilocybin drug product for treatment-resistant depression in Australia, the expected use of additional product from the production run in planned clinical research and clinical trials in the United States and Europe, the Company's ability to support patient access and clinical research in multiple jurisdictions and the anticipated benefits of the Company's updated bottling configurations. Forward-looking statements are often identified by words such as "expects," "anticipates," "believes," "intends," "plans," "may," "will," "would," "could," or similar expressions. Forward-looking statements are based on several assumptions and are subject to a number of known and unknown risks and uncertainties, many of which are beyond the Company's control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. Accordingly, there are or will be important factors that may cause actual results to differ from expected results. These factors include those described under "Risk Factors" in the Company's registration statement on Form F-1, as amended, and other filings with the U.S. Securities and Exchange Commission made from time to time which are available at www.sec.gov or in the Company's continuous disclosure filings available under its SEDAR+ profile at www.sedarplus.ca. Except as expressly required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. New factors emerge from time to time, and it is not possible for the Company to predict all of them or assess the impact of each factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Any forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement.Neither the Canadian Securities Exchange nor the Canadian Investment Regulatory Organization accepts responsibility for the adequacy or accuracy of this release.SOURCE Optimi Health Corp Original: Optimi Health Completes Commercial Psilocybin Production to Address Treatment-Resistant Depression in Australia

Optimi Health Welcomes Expanded Psychedelic-Assisted Therapy Access Under Updated Authorized Prescriber Framework in AustraliaMay 29, 2026 11:14 AM
PR Newswire (Canada) Updated TGA recommendations broaden therapist eligibility, accept a wider range of treatment settings, and reinforce Australia's position as the world's leading commercial market for prescribed psilocybin and MDMAVANCOUVER, BC, May 29, 2026 /CNW/ - via IBN – Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "Company" or "Optimi"), a commercial-stage psychedelic pharmaceutical manufacturer, today acknowledged the final recommendations published by the Therapeutic Goods Administration ("TGA") following its targeted consultation on the Authorized Prescriber ("AP") scheme for psilocybin and MDMA. Under the AP scheme, authorized psychiatrists may prescribe Optimi's MDMA for the treatment of post-traumatic stress disorder ("PTSD") and psilocybin for treatment-resistant depression ("TRD") from the Company's GMP-compliant production facility in Canada, making Australia the first country in the world to recognize, and regulate, both substances as medicines for these indications.The updated framework, published following stakeholder consultation that closed on May 19, 2026, introduces material changes to how psychedelic-assisted psychotherapy ("PAT") is delivered in Australia. The changes are designed to expand the eligible workforce, open new categories of treatment setting, and accelerate scaling of Australia's commercial program, which remains the leading reference point globally for prescribed psilocybin and MDMA care."The TGA's updated framework is a meaningful step toward unlocking the workforce, settings, and prescriber base needed to further scale psychedelic-assisted therapy in Australia," said Dane Stevens, CEO of Optimi. "After over two years of regulated commercial use, no serious adverse events have been reported under the scheme. Australia continues to be the most advanced commercial reference point for what reimbursed, real-world psychedelic care looks like, and Optimi is positioned to support that expansion as patient volumes increase."Therapy Team Composition Has Been BroadenedUnder the updated framework, the therapy dyad must include at least one therapist registered with a National Board and the AP psychiatrist is required to be physically present on-site during administration of the medicine and to conduct real-time patient screening and informed consent.The second practitioner in the dosing room may be drawn from the wider pool of suitably trained professionals, including psychotherapists, counsellors, social workers, and Aboriginal and Torres Strait Islander health workers. The AP psychiatrist is responsible for determining qualifications and competency of any additional practitioner, subject to oversight by the relevant Human Research Ethics Committee ("HREC").Australia's training ecosystem supports the Certificate in Psychedelic-Assisted Therapy ("CPAT(TM)"), delivered by Mind Medicine Australia, which has trained more than 750 clinicians. The program is accredited under Australian Medical CPD Standards, recognized by HRECs and the TGA, and offers 127+ CPD hours, clinical experience pathways, and a national alumni network.This change opens the door to genuinely multidisciplinary therapy teams. The TGA noted that the broader composition will support workforce capacity in rural and regional Australia, address shortages, and improve culturally appropriate care.Treatment Can Now Occur Outside Hospital SettingsThe TGA has confirmed that PAT can be delivered in any medically supervised environment that meets defined safety standards. Sites must provide secure Schedule 8 storage, trained staff and equipment for clinical care and resuscitation, immediate access to rescue medications, robust documentation, and a location within 15 minutes of an accredited healthcare facility with an emergency department.This represents a meaningful shift from prior assumptions that day hospital or inpatient settings were required, and aligns with stakeholder feedback that less clinical, more therapeutic environments often improve patient comfort and outcomes.Real-World Safety Profile Remains CleanAggregated data obtained from the TGA confirm that no serious adverse events have been reported under the AP scheme since December 2025. Every AP psychiatrist is required to report patient numbers and any serious adverse events to the relevant Human Research Ethics Committee, the TGA, and the applicable state health department, providing a structured real-world safety surveillance framework. Adverse event and outcome data are also being collected by the Australian Interventional Pharmacotherapy and Psychedelic Assisted Psychotherapy Research Registry ("AIPPAP-RR") hosted by the Australian National University.This clean safety profile, accumulated under regulated commercial conditions rather than a clinical trial environment, supports the case for continued program expansion.Reimbursement Now Spans Public and Private PayersCoverage for psychedelic-assisted therapy in Australia is no longer confined to private pay and now spans both sides of the funding system. Public coverage includes the Department of Veterans' Affairs ("DVA"), the National Disability Insurance Scheme ("NDIS"), and WorkCover schemes. Private coverage includes Medibank, Australia's largest private health insurer. The combination of an expanded prescriber and therapist workforce, broader site eligibility, and growing reimbursement across public and private payers creates a credible employment pathway for trained practitioners and an addressable patient population for commercial supply.About Optimi Health Corp.Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) is a commercial-stage pharmaceutical company focused on manufacturing and distributing GMP-grade psychedelic drug products for mental health therapies. As a Health Canada-licensed pharmaceutical manufacturer, Optimi produces validated MDMA and botanical psilocybin drug products at its GMP-compliant facilities in British Columbia, Canada.Optimi supplies both active pharmaceutical ingredients and finished dosage forms to regulated clinical and therapeutic programs internationally, with products currently prescribed to patients in Australia under the country's Authorized Prescriber Scheme and accessible in Canada through the Special Access Program.For more information, please visit www.optimihealth.ca or optimi.netForward-Looking StatementsThis press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws, including statements regarding the expected impact of the Therapeutic Goods Administration's updated Authorised Prescriber framework, including expanded therapist eligibility, broader treatment setting eligibility, increasing reimbursement availability, Australia's continued development as a commercial market for prescribed psilocybin and MDMA therapies, the safety and scalability of the Authorised Prescriber program, and the Company's ability to support growth in patient access and commercial demand in Australia and other international markets. Forward-looking statements are often identified by words such as "expects," "anticipates," "believes," "intends," "plans," "may," "will," "would," "could," or similar expressions. Forward-looking statements are based on several assumptions and are subject to a number of known and unknown risks and uncertainties, many of which are beyond the Company's control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. Accordingly, there are or will be important factors that may cause actual results to differ from expected results. These factors include those described under "Risk Factors" in the Company's registration statement on Form F-1, as amended, and other filings with the U.S. Securities and Exchange Commission made from time to time which are available at www.sec.gov or in the Company's continuous disclosure filings available under its SEDAR+ profile at www.sedarplus.ca. Except as expressly required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. New factors emerge from time to time, and it is not possible for the Company to predict all of them or assess the impact of each factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Any forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement.Neither the Canadian Securities Exchange nor the Canadian Investment Regulatory Organization accepts responsibility for the adequacy or accuracy of this release. View original content to download multimedia:https://www.prnewswire.com/news-releases/optimi-health-welcomes-expanded-psychedelic-assisted-therapy-access-under-updated-authorized-prescriber-framework-in-australia-302785838.htmlSOURCE Optimi Health Corp Original: Optimi Health Welcomes Expanded Psychedelic-Assisted Therapy Access Under Updated Authorized Prescriber Framework in Australia

Optimi Health Advances Highest-Purity Natural Psilocybin Extract to DateMay 26, 2026 7:00 AM
NewsfileThe 6% naturally derived extract is set to be encapsulated for use in patients suffering from treatment-resistant depression under Australia's Authorised Prescriber Scheme, where no serious adverse events have been reported as of December 2025Vancouver, British Columbia--(Newsfile Corp. - May 26, 2026) - Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "Company" or "Optimi"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the completion of a production run of naturally derived psilocybin extract measuring approximately 6% psilocybin content, representing the highest-purity botanical psilocybin extract produced by the Company to date.The milestone reflects sustained gains across Optimi's cultivation program. Drawing on a proprietary library of more than 200 distinct mushroom genetics maintained at the Company's facilities, Optimi has selectively advanced cultivars demonstrating increasingly elevated psilocybin content. Those cultivation improvements, combined with refinements to the Company's extraction process, have produced a botanical extract substantially more concentrated than prior production cycles while maintaining its naturally derived profile.A portion of the completed extract has been earmarked to support upcoming clinical research programs in Europe, where Optimi is expected to supply GMP-grade finished material into sponsor-led studies. Consistent with the Company's role as a regulated manufacturer rather than a drug-development sponsor, Optimi's contribution is the supply of psilocybin-containing finished drug products.Remaining biomass from the psilocybin production cycle will be retained at Optimi's facilities for ongoing product development, formulation refinement, and future regulated supply initiatives as international access pathways continue to expand.The milestone also reinforces Optimi's commercial supply in Australia, where the Company's naturally derived 5 mg psilocybin capsules are being prescribed for treatment-resistant depression ("TRD") under the Therapeutic Goods Administration's Authorised Prescriber Scheme. The higher-purity extract strengthens the material base supporting that supply. Optimi remains among a small number of commercial-stage companies worldwide whose psilocybin drug products are reaching patients through reimbursed treatment pathways, with eligible Australian patients accessing psilocybin-assisted therapy for TRD supported by established reimbursement initiatives.Aggregated data published in connection with Australia's Authorised Prescriber Scheme, under which Optimi has supplied psilocybin finished products since September 2025, indicate that no serious adverse events have been reported among patients treated with psilocybin under the Scheme as of December 2025."Higher purity from naturally derived material is a manufacturing achievement," said Dane Stevens, CEO and Co-Founder of Optimi Health. "We have spent years building a cultivation and extraction platform that gets stronger with every cycle. Reaching 6% psilocybin while maintaining the botanical footprint at scale is exactly the kind of progress we strive for. It strengthens supply for Australian patients, supports clinical research opportunities, and expands the development potential of infrastructure we own and operate."About Optimi Health Corp.Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) is a commercial-stage pharmaceutical company focused on manufacturing and distributing GMP-grade psychedelic drug products for mental health therapies. As a Health Canada-licensed pharmaceutical manufacturer, Optimi produces validated MDMA and botanical psilocybin drug products at its GMP-compliant facilities in British Columbia, Canada.Optimi supplies both active pharmaceutical ingredients and finished dosage forms to regulated clinical and therapeutic programs internationally, with products currently prescribed to patients in Australia under the country's Authorized Prescriber Scheme and accessible in Canada through the Special Access Program.For more information, please visit www.optimihealth.ca.For more information, please contact:
Dane Stevens, CEO
Optimi Health Corp.
(778) 761-4551
investors@optimihealth.ca
www.optimihealth.ca Investor Relations Contact:
Lucas A. Zimmerman
Managing Director
MZ Group - MZ North America
(262) 357-2918
OPTHF@mzgroup.us
www.mzgroup.us Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of applicable securities laws. Forward-looking statements are based on several assumptions and are subject to a number of risks and uncertainties, many of which are beyond the Company's control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. Accordingly, there are or will be important factors that may cause actual results to differ from expected results. These factors include those described under "Risk Factors" in the Company's registration statement on Form F-1, as amended, and other filings with the US Securities and Exchange Commission that we make from time to time which are available at www.sec.gov or in the Company's continuous disclosure filings available under its SEDAR+ profile at www.sedarplus.ca. Except as expressly required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for the Company to predict all of them or assess the impact of each factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Any forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.Neither the Canadian Securities Exchange nor the Canadian Investment Regulatory Organization accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/298817 Original: Optimi Health Advances Highest-Purity Natural Psilocybin Extract to Date

Optimi Health Announces Closing of Oversubscribed US$15 Million Public OfferingMay 21, 2026 1:07 PM
NewsfileVancouver, British Columbia--(Newsfile Corp. - May 21, 2026) - Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "Company" or "Optimi"), a commercial-stage pharmaceutical company focused on manufacturing and distributing finished psychedelic drug products, today closed its previously announced underwritten public offering (the "Offering") in connection with the uplisting of its common shares to the Nasdaq Capital Market. The Company issued 2,400,000 common shares at a price of US$6.25 per share. The aggregate gross proceeds to the Company from the Offering were US$15,000,000, before deducting underwriting discounts and offering expenses."This marks a significant milestone for Optimi," said Dane Stevens, Chief Executive Officer of Optimi. "This financing provides significant strength to our balance sheet and represents the necessary working capital for the growth of our business, with ample runway to scale over the next few years. We are thrilled to welcome a number of new, high-quality investors to our Nasdaq listing, who also see the benefits of psychedelic medicine."The common shares began trading on the Nasdaq Capital Market on May 20, 2026, under the symbol "OPTH." The Company's common shares will continue to trade on the Canadian Securities Exchange under the symbol "OPTI". All securities issued under the Offering were issued free from any resale restrictions under applicable Canadian and United States securities laws.Pursuant to an underwriting agreement dated May 19, 2026, between Joseph Gunnar & Co., LLC (the "Underwriter") and the Company, the Underwriter acted as sole book-running manager for the Offering. The Company granted 96,000 non-transferable common share purchase warrants entitling the Underwriter to purchase up to an aggregate of 96,000 common shares of the Company at a price of US$7.50 per share until May 21, 2031, and paid certain offering expenses of the Underwriter.A registration statement on Form F-1 (File No. 333-290086) related to the Offering of the shares described above was filed with the United States Securities and Exchange Commission ("SEC") and was declared effective on May 19, 2026. A copy of the registration statement can be accessed by visiting the SEC website at www.sec.gov. The common shares were offered and sold in the United States only by means of a prospectus forming part of the registration statement. A final prospectus relating to this Offering has been filed with the SEC and may be obtained from Joseph Gunnar & Co., LLC, Prospectus Department, 40 Wall Street, 30th Floor, New York, NY 10005, telephone 212-440-9600, email: prospectus@jgunnar.com. Investors may also obtain these documents at no cost by visiting the SEC's website at http://www.sec.gov.In Canada, the Offering was completed in reliance on the "listed issuer financing" exemption from the prospectus requirements available under Part 5A.2 of National Instrument 45-106 - Prospectus Exemptions, as modified by Coordinated Blanket Order 45-935 - Exemptions from Certain Conditions of the Listed Issuer Financing Exemption.This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.About Optimi Health Corp.Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) is a commercial-stage pharmaceutical company focused on manufacturing and distributing GMP-grade psychedelic drug products for mental health therapies. As a Health Canada-licensed pharmaceutical manufacturer, Optimi produces validated MDMA and botanical psilocybin drug products at its GMP-compliant facilities in British Columbia, Canada.Optimi supplies both active pharmaceutical ingredients and finished dosage forms to regulated clinical and therapeutic programs internationally, with products currently prescribed to patients in Australia under the country's Authorized Prescriber Scheme and accessible in Canada through the Special Access Program.For more information, please visit www.optimihealth.ca.Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of applicable securities laws. Forward-looking statements are based on several assumptions and are subject to a number of risks and uncertainties, many of which are beyond the Company's control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. Accordingly, there are or will be important factors that may cause actual results to differ from expected results. These factors include those described under "Risk Factors" in the Company's registration statement on Form F-1, as amended, relating to the Offering or in the Company's continuous disclosure filings available under its SEDAR+ profile at www.sedarplus.ca. Except as expressly required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for the Company to predict all of them or assess the impact of each factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Any forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.Neither the Canadian Securities Exchange nor the Canadian Investment Regulatory Organization accepts responsibility for the adequacy or accuracy of this release.Investor Relations ContactLucas A. Zimmerman
Managing Director
MZ Group - MZ North America
(262) 357-2918
OPTHF@mzgroup.us
www.mzgroup.usTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/298410 Original: Optimi Health Announces Closing of Oversubscribed US$15 Million Public Offering

Optimi Health Announces Pricing of Oversubscribed US$15 Million Public Offering and Nasdaq UplistingMay 20, 2026 11:30 AM
PR Newswire (US) Common Shares to Trade on the Nasdaq Capital Market Under the Symbol "OPTH"VANCOUVER, BC, May 20, 2026 /PRNewswire/ - Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) (the "Company" or "Optimi"), a commercial-stage pharmaceutical company focused on manufacturing and distributing finished psychedelic drug products, today announced the pricing of its underwritten public offering (the " Offering") in connection with the uplisting of its common shares to the Nasdaq Capital Market. The Company is offering 2,400,000 common shares at a public offering price of US$6.25 per share. The Company has also granted the Underwriter (as defined below) the option to purchase up to an additional 360,000 common shares. The common shares are expected to begin trading on the Nasdaq Capital Market on May 20, 2026 under the symbol "OPTH." The gross proceeds from the Offering, before deducting underwriting discounts and commissions and other estimated Offering expenses payable by the Company, are expected to be approximately US$15 million, excluding any exercise of the underwriter's option to purchase additional shares. The Offering is expected to close on or about May 21, 2026, subject to the satisfaction of customary closing conditions.The Company intends to use the net proceeds of the Offering for scaling production and distribution of its products in its current markets, additional market expansion, including the United States, and sales growth and general working capital and other operating expenses. However, the Company's management will have broad discretion with respect to the actual use of the net proceeds from the Offering.Joseph Gunnar & Co., LLC (the "Underwriter") is acting as sole book-running manager for the Offering.A registration statement on Form F-1 (File No. 333-290086) related to the Offering of the shares described above was filed with the United States Securities and Exchange Commission ("SEC") and was declared effective on May 19, 2026. A copy of the registration statement can be accessed by visiting the SEC website at www.sec.gov. The common shares are being offered and sold in the United States only by means of a prospectus forming part of the registration statement. A final prospectus relating to this Offering will be filed with the SEC. When available, a copy of the final prospectus may be obtained from Joseph Gunnar & Co., LLC, Prospectus Department, 40 Wall Street, 30th Floor, New York, NY 10005, telephone 212-440-9600, email: prospectus@jgunnar.com. Investors may also obtain these documents at no cost by visiting the SEC's website at http://www.sec.gov.Before you invest, you should read the prospectus and other documents the Company has filed or will file with the SEC for more complete information about the Company and the Offering.The Offering will be completed in each of the provinces and territories of Canada, except for Quebec, in reliance on the "listed issuer financing" exemption from the prospectus requirements available under Part 5A.2 of National Instrument 45-106 - Prospectus Exemptions, as modified by Coordinated Blanket Order 45-935 - Exemptions from Certain Conditions of the Listed Issuer Financing Exemption (the "Listed Issuer Financing Exemption"). Any distribution of common shares outside of Canada will be made pursuant to applicable foreign securities laws and the public offering exemption available under BC Instrument 72-503 – Distribution of Securities outside British Columbia.Further to the Company's news release dated April 23, 2026 announcing its intention to complete a portion of the Offering in Canada pursuant to the Listed Issuer Financing Exemption, there is an amended and restated offering document related to the Offering (the "Offering Document") that can accessed under the Company's profile on SEDAR+ at www.sedarplus.com and on the Company's website at www.optimihealth.ca. Prospective investors should read the Offering Document before making an investment decision concerning the common shares. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.The Company also announces further to its press release dated March 16, 2026, the record date for the previously announced consolidation of its outstanding common shares on the basis of one (1) post-consolidation common share for every thirty (30) pre-consolidation shares (the "Consolidation") was May 19, 2026. The Consolidation became effective as of 4:30 p.m. on May 19, 2026 and trading of the post-Consolidation common shares on the Canadian Securities Exchange will commence as of the opening of the market on May 20, 2026. The Company's common shares will trade under a new CUSIP number (68405H308) and ISIN (CA68405H3080). The exercise price and the number of common shares issuable under the Company's outstanding warrants and options have been proportionately adjusted to reflect the Consolidation. Fractional shares created as a result of the Consolidation were rounded down to the next whole share.Following the Consolidation and assuming no additional issuances, the Company expects to have approximately 3,225,881 common shares issued and outstanding, prior to rounding for fractional shares and prior to giving effect to the Offering.In connection with the Consolidation, the Company will not require a letter of transmittal from holders of common shares whose shares are held in book-entry or DRS form. All such shareholders will automatically receive the post-Consolidation Shares to which they are entitled, and Endeavour Trust Corporation, as transfer agent, will distribute the applicable DRS statements. Endeavour Trust Corporation has confirmed that all common shares of the Company held by registered shareholders as of the record date on May 19, 2026 will be processed. The Consolidation remains subject to the policies of the Canadian Securities Exchange.About Optimi Health Corp.Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) is a commercial-stage pharmaceutical company focused on manufacturing and distributing GMP-grade psychedelic drug products for mental health therapies. As a Health Canada-licensed pharmaceutical manufacturer, Optimi produces validated MDMA and botanical psilocybin drug products at its GMP-compliant facilities in British Columbia, Canada.Optimi supplies both active pharmaceutical ingredients and finished dosage forms to regulated clinical and therapeutic programs internationally, with products currently prescribed to patients in Australia under the country's Authorized Prescriber Scheme and accessible in Canada through the Special Access Program.For more information, please visit www.optimihealth.ca.Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of applicable securities laws. These forward-looking statements include, but are not limited to, statements relating to the Offering, including the anticipated completion, timing, size and terms of the Offering; the expected commencement of trading of the Company's common shares on the Nasdaq Capital Market; the intended use of proceeds from the Offering; the completion and effects of the consolidation of the Company's common shares; the Company's ability to meet applicable Nasdaq listing requirements; the completion of a portion of the Offering in Canada pursuant to the Listed Issuer Financing Exemption; the intended reliance on Coordinated Blanket Order 45-935; the receipt of required regulatory and exchange approvals, including approvals of the Canadian Securities Exchange, the Nasdaq Capital Market and the U.S. Securities and Exchange Commission; and the satisfaction of customary closing conditions.Forward-looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond the Company's control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. These assumptions include, but are not limited to, capital markets conditions and investor demand; the Company, the Underwriter and other parties being able to satisfy customary closing conditions; the Company's ability to meet applicable Nasdaq listing requirements in connection with the Offering; and the absence of material adverse changes in the Company's business, financial condition, operations or prospects. Although the Company believes that the assumptions underlying the forward-looking statements are reasonable, it cannot guarantee future results, level of activity, performance or achievements.Accordingly, there are or will be important factors that may cause actual results to differ from expected results. These factors include but are not limited to market volatility or adverse capital markets conditions; the failure to complete the Offering, the consolidation or any concurrent Canadian private placement on the anticipated terms or timeline, or at all; delays in obtaining regulatory or exchange approvals; and those described under "Risk Factors" in the Company's registration statement on Form F-1, as amended, relating to the Offering or in the Company's continuous disclosure filings available under its SEDAR+ profile at www.sedarplus.com. Except as expressly required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for the Company to predict all of them or assess the impact of each factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Any forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.Neither the Canadian Securities Exchange nor the Canadian Investment Regulatory Organization accepts responsibility for the adequacy or accuracy of this release.www.mzgroup.us View original content to download multimedia:https://www.prnewswire.com/news-releases/optimi-health-announces-pricing-of-oversubscribed-us15-million-public-offering-and-nasdaq-uplisting-302777792.htmlSOURCE Optimi Health Corp Original: Optimi Health Announces Pricing of Oversubscribed US$15 Million Public Offering and Nasdaq Uplisting

Optimi Health Announces Pricing of Oversubscribed US$15 Million Public Offering and Nasdaq UplistingMay 20, 2026 8:00 AM
NewsfileCommon Shares to Trade on the Nasdaq Capital Market Under the Symbol "OPTH"Vancouver, British Columbia--(Newsfile Corp. - May 20, 2026) - Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) (the "Company" or "Optimi"), a commercial-stage pharmaceutical company focused on manufacturing and distributing finished psychedelic drug products, today announced the pricing of its underwritten public offering (the " Offering") in connection with the uplisting of its common shares to the Nasdaq Capital Market. The Company is offering 2,400,000 common shares at a public offering price of US$6.25 per share. The Company has also granted the Underwriter (as defined below) the option to purchase up to an additional 360,000 common shares. The common shares are expected to begin trading on the Nasdaq Capital Market on May 20, 2026 under the symbol "OPTH."The gross proceeds from the Offering, before deducting underwriting discounts and commissions and other estimated Offering expenses payable by the Company, are expected to be approximately US$15 million, excluding any exercise of the underwriter's option to purchase additional shares. The Offering is expected to close on or about May 21, 2026, subject to the satisfaction of customary closing conditions.The Company intends to use the net proceeds of the Offering for scaling production and distribution of its products in its current markets, additional market expansion, including the United States, and sales growth and general working capital and other operating expenses. However, the Company's management will have broad discretion with respect to the actual use of the net proceeds from the Offering.Joseph Gunnar & Co., LLC (the "Underwriter") is acting as sole book-running manager for the Offering.A registration statement on Form F-1 (File No. 333-290086) related to the Offering of the shares described above was filed with the United States Securities and Exchange Commission ("SEC") and was declared effective on May 19, 2026. A copy of the registration statement can be accessed by visiting the SEC website at www.sec.gov. The common shares are being offered and sold in the United States only by means of a prospectus forming part of the registration statement. A final prospectus relating to this Offering will be filed with the SEC. When available, a copy of the final prospectus may be obtained from Joseph Gunnar & Co., LLC, Prospectus Department, 40 Wall Street, 30th Floor, New York, NY 10005, telephone 212-440-9600, email: prospectus@jgunnar.com. Investors may also obtain these documents at no cost by visiting the SEC's website at http://www.sec.gov.Before you invest, you should read the prospectus and other documents the Company has filed or will file with the SEC for more complete information about the Company and the Offering.The Offering will be completed in each of the provinces and territories of Canada, except for Quebec, in reliance on the "listed issuer financing" exemption from the prospectus requirements available under Part 5A.2 of National Instrument 45-106 - Prospectus Exemptions, as modified by Coordinated Blanket Order 45-935 - Exemptions from Certain Conditions of the Listed Issuer Financing Exemption (the "Listed Issuer Financing Exemption"). Any distribution of common shares outside of Canada will be made pursuant to applicable foreign securities laws and the public offering exemption available under BC Instrument 72-503 – Distribution of Securities outside British Columbia.Further to the Company's news release dated April 23, 2026 announcing its intention to complete a portion of the Offering in Canada pursuant to the Listed Issuer Financing Exemption, there is an amended and restated offering document related to the Offering (the "Offering Document") that can accessed under the Company's profile on SEDAR+ at www.sedarplus.ca and on the Company's website at www.optimihealth.ca. Prospective investors should read the Offering Document before making an investment decision concerning the common shares. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.The Company also announces further to its press release dated March 16, 2026, the record date for the previously announced consolidation of its outstanding common shares on the basis of one (1) post-consolidation common share for every thirty (30) pre-consolidation shares (the "Consolidation") was May 19, 2026. The Consolidation became effective as of 4:30 p.m. on May 19, 2026 and trading of the post-Consolidation common shares on the Canadian Securities Exchange will commence as of the opening of the market on May 20, 2026. The Company's common shares will trade under a new CUSIP number (68405H308) and ISIN (CA68405H3080). The exercise price and the number of common shares issuable under the Company's outstanding warrants and options have been proportionately adjusted to reflect the Consolidation. Fractional shares created as a result of the Consolidation were rounded down to the next whole share.Following the Consolidation and assuming no additional issuances, the Company expects to have approximately 3,225,881 common shares issued and outstanding, prior to rounding for fractional shares and prior to giving effect to the Offering.In connection with the Consolidation, the Company will not require a letter of transmittal from holders of common shares whose shares are held in book-entry or DRS form. All such shareholders will automatically receive the post-Consolidation Shares to which they are entitled, and Endeavour Trust Corporation, as transfer agent, will distribute the applicable DRS statements. Endeavour Trust Corporation has confirmed that all common shares of the Company held by registered shareholders as of the record date on May 19, 2026 will be processed. The Consolidation remains subject to the policies of the Canadian Securities Exchange.About Optimi Health Corp.Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) is a commercial-stage pharmaceutical company focused on manufacturing and distributing GMP-grade psychedelic drug products for mental health therapies. As a Health Canada-licensed pharmaceutical manufacturer, Optimi produces validated MDMA and botanical psilocybin drug products at its GMP-compliant facilities in British Columbia, Canada.Optimi supplies both active pharmaceutical ingredients and finished dosage forms to regulated clinical and therapeutic programs internationally, with products currently prescribed to patients in Australia under the country's Authorized Prescriber Scheme and accessible in Canada through the Special Access Program.For more information, please visit www.optimihealth.ca.For more information, please contact:
Dane Stevens, CEO
Optimi Health Corp.
(778) 761-4551
investors@optimihealth.ca
www.optimihealth.ca Investor Relations Contact:
Lucas A. Zimmerman
Managing Director
MZ Group - MZ North America
(262) 357-2918
OPTHF@mzgroup.us
www.mzgroup.us Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of applicable securities laws. These forward-looking statements include, but are not limited to, statements relating to the Offering, including the anticipated completion, timing, size and terms of the Offering; the expected commencement of trading of the Company's common shares on the Nasdaq Capital Market; the intended use of proceeds from the Offering; the completion and effects of the consolidation of the Company's common shares; the Company's ability to meet applicable Nasdaq listing requirements; the completion of a portion of the Offering in Canada pursuant to the Listed Issuer Financing Exemption; the intended reliance on Coordinated Blanket Order 45-935; the receipt of required regulatory and exchange approvals, including approvals of the Canadian Securities Exchange, the Nasdaq Capital Market and the U.S. Securities and Exchange Commission; and the satisfaction of customary closing conditions. Forward-looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond the Company's control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. These assumptions include, but are not limited to, capital markets conditions and investor demand; the Company, the Underwriter and other parties being able to satisfy customary closing conditions; the Company's ability to meet applicable Nasdaq listing requirements in connection with the Offering; and the absence of material adverse changes in the Company's business, financial condition, operations or prospects. Although the Company believes that the assumptions underlying the forward-looking statements are reasonable, it cannot guarantee future results, level of activity, performance or achievements. Accordingly, there are or will be important factors that may cause actual results to differ from expected results. These factors include but are not limited to market volatility or adverse capital markets conditions; the failure to complete the Offering, the consolidation or any concurrent Canadian private placement on the anticipated terms or timeline, or at all; delays in obtaining regulatory or exchange approvals; and those described under "Risk Factors" in the Company's registration statement on Form F-1, as amended, relating to the Offering or in the Company's continuous disclosure filings available under its SEDAR+ profile at www.sedarplus.ca. Except as expressly required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for the Company to predict all of them or assess the impact of each factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Any forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.Neither the Canadian Securities Exchange nor the Canadian Investment Regulatory Organization accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/298156 Original: Optimi Health Announces Pricing of Oversubscribed US$15 Million Public Offering and Nasdaq Uplisting

OPTHF one for 30 reverse split

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes

Optimi Health Launches Ibogaine Initiative as U.S. Executive Order Signals Pathway for Psychedelic Drug ProductsApril 20, 2026 6:00 AM
NewsfileThe Company's Health Canada-licensed GMP psychedelic manufacturing platform ready to serve emerging demand for ibogaine, a naturally occurring alkaloid under investigation for opioid use disorder, PTSD, and traumatic brain injuryVancouver, British Columbia--(Newsfile Corp. - April 20, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (the "Company" or "Optimi"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today launched its Ibogaine Initiative, a program to extend the Company's Health Canada-licensed GMP platform to include the manufacture and supply of ibogaine. The initiative comes as the United States has, for the first time, taken initial steps toward a federal policy framework intended to accelerate research and patient access to psychedelic drug products.Ibogaine is a naturally occurring alkaloid derived from the root bark of the Tabernanthe iboga shrub, native to Central and West Africa. It has been studied for its potential to interrupt opioid withdrawal and craving, and for its effects on substance-use disorders, post-traumatic stress disorder (PTSD), and traumatic brain injury (TBI). A 2024 Stanford-led study of U.S. Special Operations veterans, published in Nature Medicine, reported reductions in PTSD, depression, anxiety, and functional disability in a cohort following a single ibogaine treatment protocol.Optimi is commercial-stage in Australia, where authorized physicians are actively prescribing the Company's MDMA for PTSD and its naturally derived psilocybin for treatment-resistant depression (TRD). In parallel, the Company supplies pharmaceutical-grade MDMA and psilocybin to clinical trials and special access programs globally.As part of its U.S. market readiness strategy, Optimi obtained an FDA Establishment Identifier (FEI) number in 2025, supporting its ability to engage with U.S. regulatory and commercial pathways as they evolve.On April 18, 2026, U.S. President Donald Trump signed an Executive Order directing federal agencies to accelerate research, regulatory review, and patient access pathways for psychedelic drug products, including ibogaine. At the signing, FDA Commissioner Marty Makary confirmed Investigational New Drug (IND) clearance for ibogaine, enabling sponsors to advance U.S. clinical trials. The Order directs the Advanced Research Projects Agency for Health (ARPA-H) to match qualifying state-level investments in psychedelic research, beginning with a $50 million federal allocation, which may be paired with Texas's previously authorized $50 million ibogaine research commitment. The Order also extends federal Right to Try eligibility to psychedelic drug products and contemplates priority review mechanisms, such as the Commissioner's National Priority Voucher, to potentially shorten FDA review timelines.Management CommentaryDane Stevens, Chief Executive Officer and Co-Founder of Optimi Health, said:"Optimi already manufactures and supplies GMP-grade psychedelic drug products to patients under regulated frameworks, and today in Australia, doctors are prescribing our MDMA for PTSD and psilocybin for treatment-resistant depression.Taken together, these actions move ibogaine from what has historically been a fragmented, primarily offshore ecosystem toward a defined U.S. regulatory and funding pathway. The ibogaine market took shape in a meaningful way over the weekend following a U.S. Executive Order, and it will require high-quality, regulated supply. With a fully GMP, Health Canada-licensed manufacturing infrastructure in place, Optimi is well positioned to support this next phase of market development," concluded Stevens.Organizations, sponsors, and treatment providers interested in exploring ibogaine supply, research collaboration, or clinical program support are encouraged to contact Optimi at sales@optimihealth.ca. For more information, please contact:
Dane Stevens, CEO
Optimi Health Corp.
(778) 761-4551
investors@optimihealth.ca
www.optimihealth.ca Investor Relations Contact:
Lucas A. Zimmerman
Managing Director
MZ Group - MZ North America
(262) 357-2918
OPTHF@mzgroup.us
www.mzgroup.usAbout Optimi Health Corp.Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) is a leading producer of prescribed psychedelic treatments for mental health therapies. As a Health Canada-licensed, GMP compliant pharmaceutical manufacturer producing validated MDMA and botanical psilocybin products from two 10,000-square-foot facilities in British Columbia, Optimi supplies active pharmaceutical ingredients and finished dosage forms to regulated channels, with products currently in market for prescription use in Australia via the Authorized Prescriber Scheme and accessible in Canada through the Special Access Program. For more information, please visit www.optimihealth.ca.Forward-Looking StatementsThis news release contains forward-looking statements and forward-looking information within the meaning of Canadian securities legislation (collectively, "forward-looking statements"), including with respect to the role of psychedelic medicines in insured mental health care. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive uncertainties, and contingencies, certain of which are unknown. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions, or future events or performance (often, but not always, through the use of words or phrases such as "will likely result," "are expected to," "expects," "will continue," "is anticipated," "anticipates," "believes," "estimated," "intends," "plans," "forecast," "projection," "strategy," "objective," and "outlook") are not historical facts and may be forward-looking statements. These statements may involve estimates, assumptions, and uncertainties that could cause actual results or outcomes to differ materially from those expressed in such forward-looking statements. No assurance can be given that these expectations will prove to be correct, and such forward-looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release.Forward-looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond the Company's control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. Such risk factors include but are not limited to those factors which are discussed in the Company's continuous disclosure filings available under its SEDAR+ profile at www.sedarplus.ca. Except as expressly required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for the Company to predict all of them or assess the impact of each factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Any forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.Neither the Canadian Securities Exchange nor the Canadian Investment Regulatory Organization accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/293296
Original: Optimi Health Launches Ibogaine Initiative as U.S. Executive Order Signals Pathway for Psychedelic Drug Products

Optimi Health Announces Proposed Nasdaq Listing and U.S. Underwritten Public OfferingMarch 16, 2026 7:00 AM
NewsfileVancouver, British Columbia--(Newsfile Corp. - March 16, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (the "Company" or "Optimi"), a commercial-stage pharmaceutical company focused on manufacturing and distributing finished psychedelic drug products, today announced that it has commenced an underwritten public offering in the United States (the "Offering") of its common shares, no par value (the "Shares"), pursuant to a registration statement filed with the United States Securities and Exchange Commission (the "SEC"), in connection with its proposed listing on the Nasdaq Capital Market ("Nasdaq").Joseph Gunnar & Co., LLC is acting as sole book-running manager for the proposed Offering. In connection with the proposed Offering, the Company has applied to list its Shares on the Nasdaq under the symbol "OPTH". Subject to approval of the Nasdaq listing and completion of the Offering, the Company's Shares, including those currently trading on the Canadian Securities Exchange ("CSE"), are expected to be listed for trading on the Nasdaq while continuing to trade on the CSE.The Offering will be made only by means of a prospectus that forms a part of an effective registration statement in the United States and pursuant to the public offering exemption available under BC Instrument 72-503 - Distribution of Securities outside British Columbia in Canada. When available, copies of the preliminary prospectus relating to this Offering may be obtained from Joseph Gunnar & Co., LLC, Prospectus Department, 40 Wall Street, 30th Floor, New York, NY 10005, telephone 212-440-9600, email: prospectus@jgunnar.com. A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with Canadian securities laws, the registration requirements of the Securities Act of 1933, as amended, and the applicable laws of any jurisdiction where such securities are sold. The Offering is subject to market and other conditions and the completion of the SEC and Nasdaq review process. There can be no assurance as to whether or when the proposed Offering may be completed, or as to the actual size or terms of the Offering.The Shares of the Offering referenced above are not being offered to residents of Canada or persons in Canada. Any offering of securities to Canadian investors, if any, would be conducted pursuant to separate prospectus exemptions under applicable Canadian securities laws and would not form part of the Offering.ConsolidationAlthough not yet effective, the Company's board of directors has approved a consolidation of its outstanding Shares on the basis of one (1) post-consolidation common Share for every thirty (30) pre-consolidation Shares (the "Consolidation"). The Company anticipates effecting the Consolidation immediately prior to the effectiveness of the registration statement relating to these securities.The Consolidation is intended to allow the Company to meet the minimum share price requirement of the Nasdaq and is being undertaken in connection with the Company's proposed listing on Nasdaq. The Consolidation will not affect a shareholder's proportionate ownership interest in the Company, except for adjustments resulting from the treatment of fractional Shares.The Company currently has 96,776,919 Shares issued and outstanding. Following the Consolidation, the Company expects to have approximately 3,225,897 Shares issued and outstanding, prior to rounding for fractional shares and prior to giving effect to the Offering.The Company's name and stock symbol will remain unchanged following the Consolidation. The new CUSIP number will be 68405H308 and the new ISIN will be CA68405H3080 for post-Consolidation Shares.No fractional Shares will be issued if, as a result of the Consolidation, a registered shareholder would otherwise be entitled to a fractional Share. Instead, any fractional interest resulting from the Consolidation will be rounded down to the nearest whole Share. Any of the Company's outstanding incentive stock options, warrants and other convertible securities will be adjusted on the same basis (30:1) to reflect the Consolidation in accordance with their respective terms, with proportionate adjustments to be made to the exercise prices.Shareholders of the Company approved the Consolidation at an annual general and special meeting of shareholders held on September 8, 2025. No action is required to be taken by shareholders with respect to the Consolidation. Beneficial holders who hold their Shares through intermediaries (e.g., a broker, bank, trust company, investment dealer or other financial institution) and who have questions regarding how the Consolidation will be processed should contact their intermediaries.About Optimi Health Corp.Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) is a commercial-stage pharmaceutical company focused on manufacturing and distributing GMP-grade psychedelic drug products for mental health therapies. As a Health Canada-licensed pharmaceutical manufacturer, Optimi produces validated MDMA and botanical psilocybin drug products at its GMP-compliant facilities in British Columbia, Canada.Optimi supplies both active pharmaceutical ingredients and finished dosage forms to regulated clinical and therapeutic programs internationally, with products currently prescribed to patients in Australia under the country's Authorized Prescriber Scheme and accessible in Canada through the Special Access Program.On Behalf of the Board
JJ Wilson, ChairmanFor more information, please contact:
Dane Stevens, CEO
Optimi Health Corp.
(778) 761-4551
investors@optimihealth.ca
www.optimihealth.ca Investor Relations Contact:
Lucas A. Zimmerman
Managing Director
MZ Group - MZ North America
(262) 357-2918
OPTHF@mzgroup.us
www.mzgroup.us Forward-Looking StatementsThis press release contains forward-looking statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive uncertainties, and contingencies, certain of which are unknown. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions, or future events or performance (often, but not always, through the use of words or phrases such as "will likely result," "are expected to," "expects," "will continue," "is anticipated," "anticipates," "believes," "estimated," "intends," "plans," "forecast," "projection," "strategy," "objective," and "outlook") are not historical facts and may be forward-looking statements, including, but not limited to, the statements regarding the timing and completion of the proposed Offering in the United States; the timing for the SEC registration statement to become effective; Nasdaq approval of the Company's listing application and the anticipated listing of the Company's common shares on Nasdaq; the timing, implementation and effects of the proposed share consolidation; and the Company's expectations that the Offering and related transactions will satisfy applicable listing requirements and be completed on the expected timeline, or at all. These statements may involve estimates, assumptions, and uncertainties that could cause actual results or outcomes to differ materially from those expressed in such forward-looking statements. No assurance can be given that these expectations will prove to be correct, and such forward-looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release.Forward-looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond the Company's control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. These assumptions include, but are not limited to, capital markets conditions and investor demand being sufficient to complete the Offering on acceptable terms; the Company, the underwriter and other parties being able to satisfy customary closing conditions; the SEC and Nasdaq review processes proceeding on the timelines currently anticipated; the Company's ability to meet applicable Nasdaq listing requirements following the consolidation and in connection with the Offering; and the absence of material adverse changes in the Company's business, financial condition, operations or prospects. Although the Company believes that the assumptions underlying the forward-looking statements are reasonable, it cannot guarantee future results, level of activity, performance or achievements. Accordingly, there are or will be important factors that may cause actual results to differ from expected results. These factors include but are not limited to market volatility or adverse conditions that may impact the Offering; the Company's inability to obtain, or delays in obtaining, regulatory or exchange approvals; and those described under "Risk Factors" in the Company's registration statement on Form F-1, as amended, relating to the Offering or in the Company's continuous disclosure filings available under its SEDAR+ profile at www.sedarplus.com. Except as expressly required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for the Company to predict all of them or assess the impact of each factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Any forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.Neither the Canadian Securities Exchange nor the Canadian Investment Regulatory Organization accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/288439
Original: Optimi Health Announces Proposed Nasdaq Listing and U.S. Underwritten Public Offering

Optimi Health Reports Early Clinical Rollout of Natural Psilocybin Capsules for Treatment-Resistant Depression in AustraliaFebruary 26, 2026 7:00 AM
NewsfileFirst Patients of 2026 Treated Outside of Sponsor-Led Clinical Trials Under Australia's Regulated FrameworkVancouver, British Columbia--(Newsfile Corp. - February 26, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of pharmaceutical-grade psychedelic drug products, today reported that patients diagnosed with treatment-resistant depression (TRD) have now been treated in Australia using the Company's naturally derived 5 mg psilocybin capsules under the Authorised Prescriber Scheme.The clinical administration follows the Company's first psilocybin shipment of 2026 and represents the early rollout of Optimi's finished drug product across authorised clinics operating within Australia's nationally regulated access framework. Product was dispensed through Optimi's licensed Australian pharmacy partner pursuant to approved import permits prior to clinical administration. Treatments were administered by Authorised Prescribers in accordance with Australian regulatory requirements.This milestone occurs approximately six months following Optimi's initial commercial launch of psilocybin supply into Australia and reflects early-stage clinical adoption within the regulated access pathway. Prior to this, the Company completed multiple MDMA shipments for supply under Australia's Authorised Prescriber Scheme. Optimi is now supplying both psilocybin for TRD and MDMA for PTSD into Australia's nationally regulated medical framework.Both products are produced at Optimi's accredited facility in Canada and comply with the Therapeutic Goods Administration (TGA) Quality Guidelines, including TGO 112 and TGO 113, where applicable."We are seeing the Authorised Prescriber pathway function as intended — enabling regulated access for eligible patients under appropriate clinical oversight," said Ilan Hayman of Mind Medicine Australia. "The early administration of psilocybin-assisted therapy under this framework reflects careful implementation by clinicians and the continued maturation of Australia's regulated access model."Treatment data and patient-reported outcomes are being captured through Australia's national registry in partnership with Australian National University. Psilocybin-assisted therapy in Australia is prescribed through authorised programs supported by Mind Medicine Australia.Clinicians, hospital networks, and authorised programs operating under the Authorised Prescriber Scheme may seek information regarding access through Mind Medicine Australia at info@mindmedicineaustralia.org.For global enquiries outside of Australia, please contact sales@optimihealth.ca. For more information, please contact:
Dane Stevens, CEO
Optimi Health Corp.
(778) 761-4551
investors@optimihealth.ca
www.optimihealth.ca Investor Relations Contact:
Lucas A. Zimmerman
Managing Director
MZ Group - MZ North America
(262) 357-2918
OPTHF@mzgroup.us
www.mzgroup.us To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10615/285394_d2e65b24d461ba28_001full.jpgAbout Optimi Health Corp.Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) is a leading producer of prescribed psychedelic treatments for mental health therapies. As a Health Canada-licensed, GMP compliant pharmaceutical manufacturer producing validated MDMA and botanical psilocybin products from two 10,000-square-foot facilities in British Columbia, Optimi supplies active pharmaceutical ingredients and finished dosage forms to regulated channels, with products currently in market for prescription use in Australia via the Authorized Prescriber Scheme and accessible in Canada through the Special Access Program. For more information, please visit www.optimihealth.ca.Forward-Looking StatementsThis news release contains forward-looking statements and forward-looking information within the meaning of Canadian securities legislation (collectively, "forward-looking statements"), including with respect to the role of psychedelic medicines in insured mental health care. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive uncertainties, and contingencies, certain of which are unknown. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions, or future events or performance (often, but not always, through the use of words or phrases such as "will likely result," "are expected to," "expects," "will continue," "is anticipated," "anticipates," "believes," "estimated," "intends," "plans," "forecast," "projection," "strategy," "objective," and "outlook") are not historical facts and may be forward-looking statements. These statements may involve estimates, assumptions, and uncertainties that could cause actual results or outcomes to differ materially from those expressed in such forward-looking statements. No assurance can be given that these expectations will prove to be correct, and such forward-looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release.Forward-looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond the Company's control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. Such risk factors include but are not limited to those factors which are discussed in the Company's continuous disclosure filings available under its SEDAR+ profile at www.sedarplus.ca. Except as expressly required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for the Company to predict all of them or assess the impact of each factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Any forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.Neither the Canadian Securities Exchange nor the Canadian Investment Regulatory Organization accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/285394
Original: Optimi Health Reports Early Clinical Rollout of Natural Psilocybin Capsules for Treatment-Resistant Depression in Australia

Optimi Health Completes Psilocybin Export to Australia for Treatment Resistant DepressionFebruary 19, 2026 2:00 AM
NewsfileNaturally-Derived 5 mg Psilocybin Capsules Mark the Company's Second Drug in Market Under Australia's Authorised Prescriber SchemeVancouver, British Columbia--(Newsfile Corp. - February 19, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of pharmaceutical-grade psychedelic drug products, today announced the export of its GMP-manufactured natural 5 mg psilocybin capsules to Australia for the treatment of patients diagnosed with treatment-resistant depression (TRD) under Australia's Authorised Prescriber Scheme.The shipment represents Optimi's second finished drug product supplied into Australia's Authorised Prescriber Scheme, alongside the Company's 40 mg and 60 mg MDMA capsules for post-traumatic stress disorder (PTSD)."Optimi's 5 mg naturally derived psilocybin capsules are now available to patients in Australia suffering from treatment-resistant depression," said Dane Stevens, Chief Executive Officer and Co-Founder of Optimi Health. "Supplying pharmaceutical-grade psilocybin outside of traditional clinical trials within a nationally regulated framework is an important milestone for our team and shareholders. Optimi is purpose-built to control the full production lifecycle - cultivation, extraction, encapsulation, and packaging - through our proprietary GMP process, ensuring consistency, quality, and dependable supply as clinical access expands."Psilocybin-assisted therapy in Australia is available through authorised clinics, including programs supported by the Department of Veterans' Affairs (DVA). Under the current policy framework, the DVA may reimburse eligible patients for the full cost of psychedelic-assisted therapy, including both the medicine and associated psychotherapy.Optimi manufactures its finished psilocybin drug product under a Health Canada-issued Drug Establishment Licence, authorising pharmaceutical-grade production and international export for prescription use. Treatment outcomes are being captured through Australia's national patient registry in partnership with the Australian National University (ANU).Clinicians, hospital networks, and authorised programs operating under the Authorised Prescriber Scheme may seek information regarding access through Mind Medicine Australia at ilan@mindmedicineaustralia.org.For global enquiries outside of Australia, please contact sales@optimihealth.ca.For more information, please contact:
Dane Stevens, CEO
Optimi Health Corp.
Telephone: (778) 761-4551
investors@optimihealth.ca
www.optimihealth.ca Investor Relations Contact:
Lucas A. Zimmerman
Managing Director
MZ Group - MZ North America
Telephone: (262) 357-2918
OPTHF@mzgroup.us
www.mzgroup.us About Optimi Health Corp.Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) is a leading producer of prescribed psychedelic treatments for mental health therapies. As a Health Canada-licensed, GMP compliant pharmaceutical manufacturer producing validated MDMA and botanical psilocybin products from two 10,000-square-foot facilities in British Columbia, Optimi supplies active pharmaceutical ingredients and finished dosage forms to regulated channels, with products currently in market for prescription use in Australia via the Authorized Prescriber Scheme and accessible in Canada through the Special Access Program. For more information, please visit www.optimihealth.ca.Forward-Looking StatementsThis news release contains forward-looking statements and forward-looking information within the meaning of Canadian securities legislation (collectively, "forward-looking statements"), including with respect to the role of psychedelic medicines in insured mental health care. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive uncertainties, and contingencies, certain of which are unknown. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions, or future events or performance (often, but not always, through the use of words or phrases such as "will likely result," "are expected to," "expects," "will continue," "is anticipated," "anticipates," "believes," "estimated," "intends," "plans," "forecast," "projection," "strategy," "objective," and "outlook") are not historical facts and may be forward-looking statements. These statements may involve estimates, assumptions, and uncertainties that could cause actual results or outcomes to differ materially from those expressed in such forward-looking statements. No assurance can be given that these expectations will prove to be correct, and such forward-looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release.Forward-looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond the Company's control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. Such risk factors include but are not limited to those factors which are discussed in the Company's continuous disclosure filings available under its SEDAR+ profile at www.sedarplus.ca. Except as expressly required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for the Company to predict all of them or assess the impact of each factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Any forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.Neither the Canadian Securities Exchange nor the Canadian Investment Regulatory Organization accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/284435
Original: Optimi Health Completes Psilocybin Export to Australia for Treatment Resistant Depression

Optimi Health Completes First 2026 Production of MDMA and Psilocybin CapsulesJanuary 26, 2026 12:00 PM
NewsfileAustralia's Department of Health has issued import permits for Optimi's MDMA and psilocybin capsules for use under the Authorised Prescriber SchemeVancouver, British Columbia--(Newsfile Corp. - January 26, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of pharmaceutical psychedelic drug products, today reported that it has completed a production cycle for its MDMA and psilocybin capsules intended for supply into Australia under the Authorised Prescriber Scheme.The completed batch consists of 1,000 MDMA capsules in a 60 mg dosage form and 1,000 naturally derived psilocybin capsules in a 5 mg dosage form. Final packaging, labelling, and batch release were completed in accordance with Optimi's Drug Establishment Licence issued by Health Canada. The capsules are GMP-compliant and supported by Certificates of Analysis confirming conformance with applicable quality specifications, following receipt of the required Australian import permits.To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10615/281580_66f04ec31421584a_001full.jpg"This production run has been released and approved for import, allowing Optimi to continue supplying MDMA and psilocybin into Australia's regulated healthcare system," said Dane Stevens, Chief Executive Officer of Optimi Health. "Completing this first production cycle of 2026 positions us to expand access across the country for patients suffering from PTSD and TRD."Post-Traumatic Stress Disorder (PTSD) and Treatment-Resistant Depression (TRD) represent significant unmet medical needs in Australia. National data published by the Australian Bureau of Statistics indicate that approximately 5-6% of Australians experience PTSD in a given year, representing roughly 1.3 to 1.5 million people. According to the Australian Institute of Health and Welfare, more than 1.3 million Australians are affected by depressive disorders, and clinical research suggests that around one-third of individuals with major depressive disorder do not respond adequately to standard treatments.Australian clinics, hospital networks, and programs operating under the Authorised Prescriber Scheme may seek information regarding access through Mind Medicine Australia at info@mindmedicineaustralia.org. For global inquiries outside of Australia, please contact the Company at sales@optimihealth.ca.For more information, please contact:
Dane Stevens, CEO
Optimi Health Corp.
Telephone: (778) 761-4551
investors@optimihealth.ca
www.optimihealth.caInvestor Relations Contact
Lucas A. Zimmerman
Managing Director
MZ Group - MZ North America
(262) 357-2918
OPTHF@mzgroup.us
www.mzgroup.us About Optimi Health Corp.Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) is a leading producer of prescribed psychedelic treatments for mental health therapies. As a Health Canada-licensed, GMP compliant pharmaceutical manufacturer producing validated MDMA and botanical psilocybin products from two 10,000-square-foot facilities in British Columbia, Optimi supplies active pharmaceutical ingredients and finished dosage forms to regulated channels, with products currently in market for prescription use in Australia via the Authorized Prescriber Scheme and accessible in Canada through the Special Access Program. For more information, please visit www.optimihealth.ca. Forward-Looking StatementsThis news release contains forward-looking statements and forward-looking information within the meaning of Canadian securities legislation (collectively, "forward-looking statements"), including with respect to the role of psychedelic medicines in insured mental health care. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive uncertainties, and contingencies, certain of which are unknown. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions, or future events or performance (often, but not always, through the use of words or phrases such as "will likely result," "are expected to," "expects," "will continue," "is anticipated," "anticipates," "believes," "estimated," "intends," "plans," "forecast," "projection," "strategy," "objective," and "outlook") are not historical facts and may be forward-looking statements. These statements may involve estimates, assumptions, and uncertainties that could cause actual results or outcomes to differ materially from those expressed in such forward-looking statements. No assurance can be given that these expectations will prove to be correct, and such forward-looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release.Forward-looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond the Company's control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. Such risk factors include but are not limited to those factors which are discussed in the Company's continuous disclosure filings available under its SEDAR+ profile at www.sedarplus.ca. Except as expressly required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for the Company to predict all of them or assess the impact of each factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Any forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.Neither the Canadian Securities Exchange nor the Canadian Investment Regulatory Organization accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/281580
Original: Optimi Health Completes First 2026 Production of MDMA and Psilocybin Capsules

Nice! Time to add methinks :) OPTHF

Dealer’s license granted https://www.optimihealth.ca/optimi-health-dealers-license-granted-by-health-canada/

Likewise. This recent discovery of the benefits of micro-dosing
psychedelics for mental health will help so many!!! Peeps will catch on slowly, then.... $OPTHF

Been adding every week.

Just grabbed a 1k starter. What up y’all?!

WELCOME TO STEP ONE

As we all know, those who get in early get the biggest rewards :)

Great management, great board of directors!

https://www.optimihealth.ca/ Check it out!

Do some DD on this company and the medical benefits of microdosing with psilocybin or 'magic' mushrooms, and you will see why they are destined to lead the pack with this cutting edge technology!